KLP Kapitalforvaltning AS Has $90,000 Stake in Phibro Animal Health Corporation (NASDAQ:PAHC)

KLP Kapitalforvaltning AS cut its holdings in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 90.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,200 shares of the company’s stock after selling 40,500 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Phibro Animal Health were worth $90,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Phibro Animal Health by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 1,514,736 shares of the company’s stock worth $31,809,000 after purchasing an additional 20,604 shares during the period. Nuveen Asset Management LLC lifted its stake in shares of Phibro Animal Health by 21.4% during the 4th quarter. Nuveen Asset Management LLC now owns 588,001 shares of the company’s stock worth $12,348,000 after buying an additional 103,618 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Phibro Animal Health by 1.9% during the 4th quarter. Renaissance Technologies LLC now owns 557,800 shares of the company’s stock worth $11,714,000 after buying an additional 10,600 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Phibro Animal Health by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 515,979 shares of the company’s stock worth $10,838,000 after buying an additional 8,510 shares during the period. Finally, CastleKnight Management LP grew its stake in Phibro Animal Health by 6.2% in the 4th quarter. CastleKnight Management LP now owns 389,433 shares of the company’s stock valued at $8,178,000 after buying an additional 22,796 shares during the last quarter. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Trading Down 5.1%

Shares of NASDAQ:PAHC opened at $26.50 on Friday. The business’s 50 day simple moving average is $26.64 and its 200 day simple moving average is $23.25. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $31.80. The company has a debt-to-equity ratio of 2.67, a current ratio of 2.91 and a quick ratio of 1.23. The company has a market capitalization of $1.07 billion, a P/E ratio of 33.97, a P/E/G ratio of 0.47 and a beta of 0.75.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, May 7th. The company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.11. The firm had revenue of $347.80 million during the quarter, compared to the consensus estimate of $352.41 million. Phibro Animal Health had a return on equity of 30.51% and a net margin of 2.68%. On average, research analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 24th. Shareholders of record on Wednesday, September 3rd will be paid a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Wednesday, September 3rd. Phibro Animal Health’s dividend payout ratio is presently 61.54%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. BNP Paribas upgraded shares of Phibro Animal Health to a “hold” rating in a research report on Monday, June 16th. JPMorgan Chase & Co. raised Phibro Animal Health from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $25.00 to $35.00 in a report on Monday, July 7th. Morgan Stanley set a $26.00 price target on Phibro Animal Health and gave the company an “equal weight” rating in a research note on Wednesday, June 25th. BNP Paribas Exane upgraded Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 price objective on the stock in a research report on Monday, June 16th. Finally, Wall Street Zen raised Phibro Animal Health from a “hold” rating to a “buy” rating in a report on Friday, May 9th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $24.40.

Phibro Animal Health Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.